| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.66▼ | 4.67▼ | 4.67▼ | 4.78▼ | 4.65▼ |
| MA10 | 4.67▼ | 4.63▲ | 4.68▼ | 4.93▼ | 4.25▲ |
| MA20 | 4.63▲ | 4.78▼ | 4.82▼ | 4.67▼ | 3.70▲ |
| MA50 | 4.82▼ | 4.90▼ | 4.97▼ | 4.13▲ | 3.24▲ |
| MA100 | 4.89▼ | 5.03▼ | 4.86▼ | 3.79▲ | 2.93▲ |
| MA200 | 5.00▼ | 4.67▼ | 4.43▲ | 3.33▲ | 3.45▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.011▲ | -0.004▼ | -0.014▼ | -0.065▼ | 0.132▲ |
| RSI | 40.794▼ | 38.841▼ | 37.905▼ | 52.489▲ | 59.942▲ |
| STOCH | 36.852 | 56.877 | 36.597 | 25.136 | 67.705 |
| WILL %R | -50.000 | -64.211 | -67.619 | -69.178 | -34.237 |
| CCI | -53.310 | -25.123 | -45.747 | -136.643▼ | 84.950 |
|
Tuesday, July 07, 2020 12:00 PM
Anavex Life Sciences is developing drugs for the treatment of Alzheimer's disease, Parkinson's disease, frontotemporal dementia, Rett Syndrome, fragile X, Angelman syndrome, and infantile spasms.
|
|
Monday, July 06, 2020 04:55 AM
(NASDAQ:AVXL) enrolls the first participant in a Phase 1 clinical trial of ANAVEX3-71 (AF710B), an orally-administered small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to ...
|
|
Monday, July 06, 2020 04:00 AM
NEW YORK, (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 08/07/20 | 4.69 | 4.69 | 4.65 | 4.65 | 55,531 |
| 07/07/20 | 4.64 | 4.72 | 4.55 | 4.65 | 460,053 |
| 06/07/20 | 4.98 | 4.98 | 4.43 | 4.65 | 1,119,500 |
| 02/07/20 | 5.06 | 5.06 | 4.875 | 4.95 | 479,700 |
| 01/07/20 | 5.00 | 5.18 | 4.85 | 5.00 | 654,859 |
| 30/06/20 | 5.04 | 5.085 | 4.84 | 4.92 | 863,501 |
| 29/06/20 | 5.18 | 5.32 | 5.00 | 5.07 | 735,400 |
| 26/06/20 | 5.12 | 5.41 | 4.91 | 5.09 | 1,824,800 |
| 25/06/20 | 5.01 | 5.45 | 4.98 | 5.20 | 894,443 |
| 24/06/20 | 4.99 | 5.21 | 4.82 | 5.08 | 908,500 |
|
|
||||
|
|
||||
|
|